- Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); de Novo Myelodysplastic Syndromes; Previously Treated Myelodysplastic Syndromes; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: tosedostat; Drug: cytarabine; Drug: decitabine
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012 - Conditions: Carcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer
Interventions: Drug: CC-223; Drug: Erlotinib; Drug: Oral azacitidine
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified April 2012 - Condition: Leukemia
Interventions: Drug: Azacytidine; Drug: GM-CSF
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Conditions: AML; MDS
Intervention: Procedure: FLT-PET scans
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison
Not yet recruiting - verified February 2012 - Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Drug: azacitidine; Drug: lenalidomide; Drug: vorinostat
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute
Interventions: Drug: oral azacitidine; Drug: oral azacitidine
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified April 2012 - Condition: Leukemia
Interventions: Drug: Dasatinib; Drug: Decitabine; Drug: Decitabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Not yet recruiting - verified April 2012 - Condition: Relapsed or Refractory Solid Tumors
Interventions: Drug: Oral azacitidine plus Abraxane; Drug: Carboplatin; Drug: Abraxane
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified April 2012 - Condition: Leukemia
Interventions: Drug: Azacitidine (AZA); Drug: Tyrosine kinase inhibitor (TKI); Drug: Azacitidine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Not yet recruiting - verified April 2012 - Condition: Graft Versus Host Disease
Interventions: Drug: Cyclophospahmide and Sirolimus; Drug: Low dose IL-2, Cyclophosphamide and Sirolimus; Drug: Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus
Sponsors: Hackensack University Medical Center; Hackensack University Medical Center
Recruiting - verified October 2011 - Conditions: Leukemia; Acute Myeloid Leukemia (AML); Myelodysplastic Syndromes (MDS)
Interventions: Drug: Azacitidine; Drug: Lenalidomide
Sponsors: Stanford University; Stanford University; Celgene Corporation
Recruiting - verified September 2011 - Conditions: Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
Interventions: Drug: azacitidine; Other: laboratory biomarker analysis; Other: flow cytometry; Drug: systemic chemotherapy; Biological: therapeutic allogeneic lymphocytes
Sponsors: Washington University School of Medicine; Washington University School of Medicine; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012 - Condition: Low and Intermediate 1 Risk MDS
Intervention: Drug: Lenalidomide and azacitidine combination
Sponsors: Rush University Medical Center; Rush University Medical Center; Celgene Corporation
Recruiting - verified June 2011 - Conditions: Acute Myeloid Leukemia; Acute Myelogenous Leukemia
Interventions: Drug: Azacitidine; Drug: Lenalidomide - single agent; Drug: Lenalidomide in combination
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012 - Conditions: Esophageal Cancer; Malignant Neoplasm of Cardio-esophageal Junction of Stomach
Interventions: Drug: Azacitidine; Drug: Azacitidine; Drug: Azacitidine; Drug: Oxaliplatin; Drug: Oxaliplatin; Drug: Epirubicin; Drug: Epirubicin; Drug: Capecitabine; Drug: Capecitabine
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified June 2011 - Condition: Breast Cancer
Interventions: Drug: azacitidine; Drug: entinostat; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Chronic Myelomonocytic Leukemia
Intervention: Drug: 5-Azacitidine
Sponsors: University of Utah; University of Utah; Celgene Corporation
Recruiting - verified January 2012 - Condition: Acute Myeloid Leukemia
Interventions: Drug: Entinostat; Drug: 5-azacitidine
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified April 2012 - Conditions: Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer
Interventions: Drug: azacitidine; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: polymerase chain reaction; Genetic: western blotting; Genetic: nucleic acid sequencing; Procedure: therapeutic conventional surgery
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Myelodysplastic Syndrome; Myelofibrosis; Chronic Myeloid Leukemia; Chronic Lymphocytic Leukemia
Interventions: Drug: Luitpold Azacitidine; Drug: Vidaza®
Sponsors: Luitpold Pharmaceuticals; Luitpold Pharmaceuticals
Recruiting - verified June 2011 - Condition: Leukemia
Interventions: Drug: Azacitidine; Drug: Sorafenib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bayer; Onyx Therapeutics, Inc.; Celgene Corporation
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Drug: azacitidine; Drug: cytarabine; Drug: etoposide phosphate; Drug: mitoxantrone hydrochloride; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Arthur G. James Cancer Hospital & Richard J. Solove Research Institute; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Neuroblastoma; Ewings Sarcoma; Osteogenic Sarcoma; Rhabdomyosarcoma; Synovial Sarcoma
Intervention: Biological: Autologous dendritic cell vaccine with adjuvant
Sponsors: Penn State University; Penn State University; Solving Kids’ Cancer
Recruiting - verified January 2012 - Conditions: Myelodysplastic Syndromes; MDS; RAEB; Chronic Myelomonocytic Leukemia
Intervention: Drug: ON 01910.Na
Sponsors: Onconova Therapeutics, Inc.; Onconova Therapeutics, Inc.; The Leukemia and Lymphoma Society
Recruiting - verified April 2012 - Conditions: Lung Cancer; Non Small Cell Lung Carcinoma; Hypermethylation
Interventions: Drug: Cisplatin; Drug: Carboplatin; Drug: Paclitaxel; Drug: Vidaza; Procedure: Tumor Specimen for Methylation Analysis; Procedure: Blood Sample for Methylation Analysis; Drug: Vinorelbine; Drug: Docetaxel; Drug: Pemetrexed
Sponsors: University of Miami Sylvester Comprehensive Cancer Center; University of Miami Sylvester Comprehensive Cancer Center
Recruiting - verified October 2011 - Condition: Leukemia
Interventions: Drug: 5-azacytidine; Drug: PKC412
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis Pharmaceuticals
Recruiting - verified January 2012 - Condition: Colorectal Cancer
Interventions: Drug: Azacitidine; Drug: Capecitabine; Drug: Oxaliplatin; Drug: Azacitidine MTD
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Recruiting - verified March 2012 - Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Biological: anti-thymocyte globulin; Drug: azacitidine; Drug: busulfan; Drug: fludarabine phosphate; Drug: methotrexate; Drug: tacrolimus; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Pancreatic Cancer
Intervention: Drug: Vidaza
Sponsors: University of Oklahoma; University of Oklahoma; Celgene Corporation
Recruiting - verified March 2012 - Condition: Refractory Multiple Myeloma
Interventions: Drug: azacitidine; Drug: lenalidomide; Drug: dexamethasone; Other: DNA methylation analysis; Other: gene expression analysis; Other: bone marrow aspiration; Other: immunohistochemistry staining method; Other: reverse transcriptase-polymerase chain reaction; Other: flow cytometry
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Hepatosplenic T-cell Lymphoma; Peripheral T-cell Lymphoma; Post-transplant Lymphoproliferative Disorder; Prolymphocytic Leukemia; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Small Intestine Lymphoma; T-cell Large Granular Lymphocyte Leukemia
Interventions: Drug: azacitidine; Drug: bortezomib; Other: laboratory biomarker analysis; Other: pharmacological study; Genetic: protein expression analysis; Genetic: gene expression analysis; Genetic: DNA methylation analysis; Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry; Genetic: microarray analysis; Other: enzyme-linked immunosorbent assay; Other: liquid chromatography; Other: mass spectrometry; Genetic: reverse transcriptase-polymerase chain reaction
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center; Millennium Pharmaceuticals, Inc.; Celgene Corporation
Recruiting - verified November 2011 - Conditions: Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Chronic Myelogenous Leukemia; B-cell Chronic Lymphocytic Leukemia; Myelodysplasia
Interventions: Drug: ABT-348; Drug: ABT-348; Drug: ABT-348 and azacitidine
Sponsors: Abbott; Abbott
Recruiting - verified February 2012 - Conditions: Hematopoietic/Lymphoid Cancer; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: midostaurin; Drug: azacitidine; Other: laboratory biomarker analysis; Other: bone marrow aspiration; Other: liquid chromatography; Other: flow cytometry; Other: mutation analysis; Other: pharmacological study; Other: mass spectrometry; Other: protein expression analysis
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center
Recruiting - verified March 2012 - Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Childhood Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes
Interventions: Drug: azacitidine; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Acute Myeloid Leukemia
Interventions: Drug: A: Azacitidine (Vidaza); Drug: B: Conventional Care Regimen
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified March 2012 - Conditions: Follicular Lymphoma; Marginal Zone Lymphoma
Interventions: Drug: azacitidine; Drug: lenalidomide
Sponsors: Duke University; Duke University; Celgene Corporation
Recruiting - verified June 2011 - Condition: Myelodysplastic Syndromes
Interventions: Drug: G-CSF, Plerixafor and Azacitidine; Drug: G-CSF, Plerixafor and Azacitidine; Drug: G-CSF, Plerixafor and Azacitidine
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011 - Condition: Multiple Myeloma
Interventions: Biological: therapeutic autologous lymphocytes; Drug: azacitidine; Drug: lenalidomide
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University; National Cancer Institute (NCI); Celgene Corporation
Recruiting - verified April 2012 - Conditions: Advanced Cancer; Solid Tumor; Lymphoma
Interventions: Drug: 5-azacytidine; Drug: Oxaliplatin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI); Celgene Corporation
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Drug: 5-Azacytidine; Drug: Lenalidomide
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Recruiting - verified April 2012 - Condition: Leukemia, Myeloid, Acute
Interventions: Drug: Azacitidine and Lenalidomide; Drug: Azacitidine and Lenalidomide; Drug: Azacitidine and Lenalidomide; Drug: Azacitidine and Lenalidomide
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011 - Condition: Leukemia, Myeloid, Acute
Interventions: Drug: Decitabine and Bexarotene; Drug: Decitabine and Bexarotene; Drug: Decitabine and Bexarotene
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011 - Conditions: Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
Interventions: Drug: Decitabine 5 mg/m2/day; Drug: Decitabine 7.5mg /m2/day; Drug: Decitabine 10 mg/m2/day
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011 - Condition: Leukemia
Interventions: Drug: Vorinostat; Drug: Azacitidine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Merck
Recruiting - verified March 2012 - Conditions: Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Acute Myeloid Leukemia
Interventions: Drug: Panobinostat (LBH589) and 5-Azacytidine; Drug: 5-Azacytidine
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012 - Condition: Renal Cell Carcinoma
Interventions: Drug: Bevacizumab; Drug: Azacitidine
Sponsors: University of Kansas; University of Kansas; Celgene Corporation
Recruiting - verified October 2011 - Conditions: Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome
Interventions: Drug: MLN4924; Drug: MLN4924 and azacitidine
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2012 - Condition: Leukemia
Interventions: Drug: azacitidine; Drug: gemtuzumab ozogamicin; Drug: vorinostat; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Leukemia; AML; MDS
Intervention: Drug: Azacitidine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)Conditions: Stem Cell Transplantation; Leukemia
Interventions: Drug: Fludarabine; Drug: Busulfan; Drug: Thymoglobulin; Drug: Azacitidine; Procedure: Stem Cell Transplant
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Acute Myeloid Leukemia
Intervention: Drug: 5-Azacitidine, Mylotarg
Sponsors: University of California, San Diego; University of California, San Diego; Celgene Corporation; Pfizer
Recruiting - verified February 2012 - Conditions: Advanced or Metastatic Solid Tumors; Advanced or Metastatic Breast Cancer
Interventions: Drug: Azacitidine (Vidaza); Drug: Nab-paclitaxel (Abraxane)
Sponsors: University of South Alabama; University of South Alabama; Celgene Corporation
Recruiting - verified August 2011 - Conditions: Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
Interventions: Drug: LBH589; Drug: Decitabine
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified September 2011 - Conditions: MDS; AML; Solid Tumors; Multiple Myeloma; Non-Hodgkin's Lymphoma; Hodgkin's Disease
Interventions: Drug: azacitidine; Drug: azacitidine; Drug: azacitidine; Drug: azacitidine; Drug: azacitidine; Drug: azacitidine; Drug: azacitidine
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified March 2012 - Conditions: Soft Tissue Sarcoma; Mesothelioma
Intervention: Drug: Azacitidine In Combination With Temozolomide
Sponsors: Columbia University; Columbia University; Schering-Plough; Celgene Corporation
Recruiting - verified October 2011 - Conditions: Prostate Cancer; Pain
Interventions: Drug: Azacitidine; Drug: Docetaxel; Drug: Prednisone; Genetic: Azacitidine induced demethylation of repetitive elements.; Genetic: GADD45α methylation and expression in prostate cancer tissue; Genetic: GADD45α methylation in serum DNA
Sponsors: University of Miami Sylvester Comprehensive Cancer Center; University of Miami Sylvester Comprehensive Cancer Center
Recruiting - verified March 2012
 |
Azacitidine Clinical Trials |
